Regeneron Pharmaceuticals Inc (REGN)vsTscan Therapeutics Inc (TCRX)
REGN
Regeneron Pharmaceuticals Inc
$749.47
+1.05%
HEALTHCARE · Cap: $78.41B
TCRX
Tscan Therapeutics Inc
$1.04
+0.97%
HEALTHCARE · Cap: $58.61M
Smart Verdict
WallStSmart Research — data-driven comparison
Regeneron Pharmaceuticals Inc generates 138814% more annual revenue ($14.34B vs $10.32M). REGN leads profitability with a 31.4% profit margin vs 0.0%. REGN earns a higher WallStSmart Score of 58/100 (C).
REGN
Buy58
out of 100
Grade: C
TCRX
Hold40
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-165.8%
Fair Value
$281.93
Current Price
$749.47
$467.54 premium
Intrinsic value data unavailable for TCRX.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Keeps 31 of every $100 in revenue as profit
Safe zone — low bankruptcy risk
Large-cap with strong market position
Attractively priced relative to earnings
Reasonable price relative to book value
Strong operational efficiency at 23.1%
Reasonable price relative to book value
Areas to Watch
Expensive relative to growth rate
2.5% revenue growth
Weak financial health signals
Earnings declined 2.6%
2.9% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Comparative Analysis Report
WallStSmart ResearchBull Case : REGN
The strongest argument for REGN centers on Profit Margin, Altman Z-Score, Market Cap. Profitability is solid with margins at 31.4% and operating margin at 23.1%.
Bull Case : TCRX
The strongest argument for TCRX centers on Price/Book.
Bear Case : REGN
The primary concerns for REGN are PEG Ratio, Revenue Growth, Piotroski F-Score.
Bear Case : TCRX
The primary concerns for TCRX are Revenue Growth, EPS Growth, Market Cap.
Key Dynamics to Monitor
TCRX carries more volatility with a beta of 1.03 — expect wider price swings.
TCRX is growing revenue faster at 2.9% — sustainability is the question.
REGN generates stronger free cash flow (922M), providing more financial flexibility.
Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.
Bottom Line
REGN scores higher overall (58/100 vs 40/100), backed by strong 31.4% margins. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Regeneron Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York. Originally focused on neurotrophic factors and their regenerative capabilities, giving rise to its name, the company then branched out into the study of both cytokine and tyrosine kinase receptors.
Tscan Therapeutics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Tscan Therapeutics Inc (TCRX) is a clinical-stage biotechnology firm that specializes in advancing immunotherapy through its proprietary T cell receptor (TCR) discovery platform, targeting specific cancer antigens to offer precision medicine solutions in oncology. The company is focused on developing innovative TCR-based therapeutics aimed at translating scientific advancements into effective treatment options for various cancers and diseases, ultimately improving patient outcomes. With a strong therapeutic pipeline and a comprehensive intellectual property portfolio, Tscan Therapeutics is well-positioned to become a leader in the rapidly evolving landscape of T cell-based therapies.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?